Monitor upcoming clinical data readouts at EULAR (June 2026) and ASCO (June 2026) for FT819 and FT836, respectively. The CDRP selection and RMAT designation provide regulatory tailwinds, but the stock remains binary on Phase 2 data. The extended cash runway removes near-term dilution risk.
FATE drugs
FATE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $2.14entry
- T+1 · 6mo ago −11.21%α −11.99% · $1.90
- T+5 · 6mo ago −11.68%α −10.52% · $1.89
- T+20 · 5mo ago −7.94%α −7.33% · $1.97
- T+60 · 3mo ago +30.84%α +26.40% · $2.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in Q1 2025, and revenue of $1.3M from its Ono collaboration. The key catalysts are regulatory and clinical: FT819 was selected for the FDA's CDRP program, the Phase 2 RECLAIM-LN trial is on track for H2 2026, and the operating runway was extended into 2028 with $174.8M in cash. However, the company remains a pre-revenue clinical-stage biotech with no approved products and a net loss of $31.2M for the quarter.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and investments of $174.8M as of March 31, 2026, providing runway into 2028
- Net loss of $31.2M for Q1 2026, improved from $37.6M loss in Q1 2025
- Revenue of $1.3M from Ono Pharmaceutical collaboration, down from $1.6M in Q1 2025
- FT819 selected for FDA's CDRP program, potentially accelerating regulatory pathway
- Phase 2 RECLAIM-LN trial for lupus nephritis on track to initiate in H2 2026
- FT819 Phase 1 enrollment at 27 patients across 18 global sites as of May 5, 2026
- FT836 Phase 1 solid tumor study has treated 9 patients; FT839 IND submission planned for H2 2026
- Operating expenses reduced 20% YoY to $34.3M in Q1 2026
- Total operating expenses of $34.3M included $3.9M non-cash stock-based compensation
Financial Impact
No material financial impact from this filing; company is pre-revenue with $174.8M cash runway into 2028
Risk Factors
- Clinical trial failure or delay in RECLAIM-LN or other programs
- Regulatory setbacks despite CDRP and RMAT designations
- Cash burn rate of ~$10.4M/month may require future capital raises
- Competition from approved CAR-T therapies and other autoimmune treatments
- Dependence on Ono collaboration for revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-220691 |
| Document: fate-20260513.htm | 0001193125-26-220691 |
| Document: 0001193125-26-220691-index-headers.html | 0001193125-26-220691 |
| Document: 0001193125-26-220691-index.html | 0001193125-26-220691 |
| Document: 0001193125-26-220691.txt | 0001193125-26-220691 |
| 8-K Data (Synthetic) | 0001193125-26-220691 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers